SPEC Participation at AMCP Nexus 2024
Join CEVR’s SPEC team in at the 2024 AMCP Nexus meeting in Las Vegas as we present our research on biosimilar coverage, using real world data to inform managed care, coverage paradigms for obesity drugs, and more
We would also like to congratulate Fariel LaMountain, SPEC Research Assistant, whose work on coverage of adalimumab products has been recognized with a Platinum Ribbon by AMCP. This award is granted to the four top abstracts submitted for the meeting and will be presented by Molly Beinfeld.
Tuesday October 15th
- 3:30 - 4:45 pm: Educational Session W3. Are Patients Getting a Fair Share of the Value of Biosimilars? Faculty: James D. Chambers, PhD
- 3:30 - 4:45 pm: Research Podium Session R3 Leveraging Real-Word Data to Advance Managed Care Pharmacy Practice. Faculty: Molly T. Beinfeld, MPH
Wednesday October 16th
- 11:30 am - 1:00 pm: Poster Presentation C34 Impact of coverage policy complexity and restrictiveness on supportive care receipt in a real-world cohort of patients with cancer. Author: Zachary Rivers, PhD
- 11:30 am - 1:00 pm: Poster Presentation E33 US commercial health plan coverage of semaglutide and tirzepatide for obesity management. Author: Dan Enright, MS
- 1:00 - 2:30 pm: Poster Presentation H4 Examining trends in coverage and access for anti-VEGF therapies in the treatment of retinal diseases among various payers from the Tufts University SPEC database. Author: James Chambers, PhD
- 1:00 - 2:30 pm: Poster Presentation U14 Alignment of commercial health plan utilization management criteria with clinical treatment guidelines. Author: Julia Rucker, MSW/MPH
- 1:00 - 2:30 pm: Poster Presentation U34 Trends in US Health Plan Coverage for Adalimumab Products. Author: Fariel LaMountain, BA
- 2:30 - 3:45 pm: Educational Session M5. Current Patterns, Future Shifts, and Best Practices in U.S. Specialty Drug Coverage. Faculty: James D. Chambers, PhD
